Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
Show 6 more subcategories
Products of "Angiogenesis"
Sort by
TrxR/EGFR-IN-1
CAS:TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.Formula:C24H24AuClFN6O2PColor and Shape:SolidMolecular weight:710.878Fumagillin
CAS:Stability Light Sensitive Applications Fumagillin is a compound isolated from the fungus Aspergillus fumigatus. Fumagillin is an antimicrobial agent used in the treatment of microsporidiosis. Fumagillin shows promise as both an an anti-infective and antiangiogenic agent. References Molina, J.M. et al.: N. Eng. J. Med., 346, 1963 (2002); Hou, L. et al.: Pathol. Int., 59, 448 (2009); Ingber, D. et al.: Nature, 348, 555 (1990);Formula:C26H34O7Color and Shape:NeatMolecular weight:458.54Atrasentan
CAS:Controlled ProductApplications Atrasentan is a selective antagonist of the endothelin-A (ETA) receptor and binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation. References Bax, W., et al.: Trends Pharmacol. Sci., 15, 379 (1994); Winn, M., et al.: J. Med. Chem., 39, 1039 (1996); Wu-Wong, J., et al.: J. Pharmacol. Exp. Ther., 281, 791 (1997);Formula:C29H38N2O6Color and Shape:Off-WhiteMolecular weight:510.62Pazopanib-d3 Hydrochloride
CAS:Controlled ProductApplications Pazopanib-d3 is the isotope labelled analog of Pazopanib (P210925), an oral angiogenesis inhibitor targeting VEGFR and PDGFR. References Olaussen, K., et al.: Oncogen., 28, 4249 (2009), Sleijfer, S., et al.: J. Clin. Oncol., 27, 3126 (2009), Chan, A., et al.: Drugs, 69, 167 (2009),Formula:C21H21D3ClN7O2SColor and Shape:NeatMolecular weight:477.0PROTAC FGFR1 degrader-1
PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.Formula:C46H54N8O8Color and Shape:SolidMolecular weight:846.97N-(4-Chloro-2-pyrimidinyl)-2,3-dimethyl-2H-indazol-6-amine
CAS:Controlled ProductApplications N-(4-Chloro-2-pyrimidinyl)-2,3-dimethyl-2H-indazol-6-amine is an intermediate in the synthesis of 5-((2-((2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-4-yl)amino)-2-methylbenzenesulfonamide Hydrochloride (D474433) which is an impurity of Pazopanib (P210925), which is an oral angiogenesis inhibitor targeting VEGFR and PDGFR. References Olaussen, K., et al.: Oncogen., 28, 4249 (2009), Sleijfer, S., et al.: J. Clin. Oncol., 27, 3126 (2009), Chan, A., et al.: Drugs, 69, 167 (2009),Formula:C13H12ClN5Color and Shape:NeatMolecular weight:273.72Protein kinase inhibitor 10
CAS:Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.Formula:C14H9FN6S2Color and Shape:SolidMolecular weight:344.39Tivozanib
CAS:Tivozanib (KRN951) is an oral VEGFRs 1-3 inhibitor with potential antiangiogenic and cancer-fighting properties.Formula:C22H19ClN4O5Purity:97.41% - 99.67%Color and Shape:SolidMolecular weight:454.86Ref: TM-T2456
2mg40.00€5mg60.00€10mg84.00€25mg142.00€50mg240.00€100mg427.00€200mg630.00€1mL*10mM (DMSO)66.00€Cavutilide
CAS:Cavutilide has antiarrhythmic activity, inhibits hERG K(+) channels, and can be used to study heart failure and persistent atrial fibrillation.Formula:C22H26FN3O3Purity:99.26% - 99.70%Color and Shape:SolidMolecular weight:399.458FM19G11
CAS:FM19G11 is an inhibitor of hypoxia inducible factor (HIF) α-subunit (IC50 = 80 nM in hypoxia induced luciferase assay).Formula:C23H17N3O8Purity:97.28%Color and Shape:SolidMolecular weight:463.4Acriflavine Hydrochloride
CAS:Acriflavine HCl is a HIF-1α inhibitor reducing PGK1, VEGF, and HIF-1α levels both in vitro and in vivo.Formula:C14H14ClN3Purity:99.69%Color and Shape:SolidMolecular weight:259.73Pazopanib Hydrochloride
CAS:Controlled ProductApplications The Hydrochloride salt of Pazopanib (P210925) a oral angiogenesis inhibitor targeting VEGFR and PDGFR. References Sleijfer, S., et al.: J. Clin. Oncol., 27, 3126 (2009), Chan, A., et al.: Drugs, 69, 167 (2009),Formula:C21H23N7O2S·ClHColor and Shape:Off-WhiteMolecular weight:473.98Apatinib-d8 25-N-Oxide Dihydrochloride
CAS:Controlled ProductApplications Labelled Apatinib 25-N-Oxide (A726160). Apatinib 25-N-Oxide is a metabolite of the antiangiogenic agent and selective VEGFR2 inhibitor Apatinib (A726150). References Ding, J, et al.: J. Chrom B Anal. Technol. Biomed. Life Sci., 895, 108 (2012);Formula:C24H15D8N5O2•2HClColor and Shape:NeatMolecular weight:421.5223646CGP062464
CAS:CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.Formula:C18H14N4Color and Shape:SolidMolecular weight:286.331Cabozantinib hydrochloride
CAS:Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Formula:C28H25ClFN3O5Purity:99.97%Color and Shape:SolidMolecular weight:537.96Ref: TM-T5164
1mg44.00€2mg55.00€5mg69.00€10mg97.00€25mg169.00€50mg248.00€100mg349.00€200mg568.00€500mg908.00€lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468Hck-IN-2
Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.Formula:C36H35FN6O10Color and Shape:SolidMolecular weight:730.696Bisphenol Z-d6
CAS:Controlled ProductApplications Bisphenol Z-d6 is the isotope labelled analog of Bisphenol Z. Bisphenol Z is one of the many derivatives of Bisphenol A (B519495) that can be used as HIF (hypoxia-inducible factor) inhibitors, antitumor agents, angiogenesis inhibitors, and antihypoxic agents. References Imaoka, S., Bisphenol A derivatives as HIF inhibitors. Jpn. Kokai Tokkyo Koho. JP 2011195574 A 20111006. Oct 6, 2011Formula:C18D6H14O2Color and Shape:NeatMolecular weight:274.387Suberoylanilide-d5 Hydroxamic Acid
CAS:Controlled ProductApplications A potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Induces differentiation in uman breast cancer cells. References Richon, V.M., et al.: Proc. Natl. Acad.Sci. USA, 95, 3003 (1988), Munster, P.N., et al.: Cancer Res., 61, 8492 (2001), Deroanne, C.F., et al.: Oncogene, 21, 247 (2002),Formula:C14H15D5N2O3Color and Shape:NeatMolecular weight:269.35Pazopanib
CAS:Controlled ProductApplications An oral angiogenesis inhibitor targeting VEGFR and PDGFR. References Olaussen, K., et al.: Oncogen., 28, 4249 (2009), Sleijfer, S., et al.: J. Clin. Oncol., 27, 3126 (2009), Chan, A., et al.: Drugs, 69, 167 (2009),Formula:C21H23N7O2SColor and Shape:NeatMolecular weight:437.52
